Clinical Trial Update: Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates preoperative amivantamab, with or without carboplatin/pemetrexed, in patients with resectable EGFR-mutant non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: University Hospital, Essen | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING